Table 2.

Cardiotoxicity of the most common treatment protocols in different hematologic malignancies (according to National Cancer Comprehensive Network, www.nccn.org, accessed on 19 June 2022).

Type of Malignancy	Protocols	Cardiotoxicity
1. Hodgkin Lymphoma	1st line 1. ABVD: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine 2. B + AVD: Brentuximab Vedotin, Doxorubicin, Vinblastine, Dacarbazine 3. BEACOPP escalated: Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisolone	Heart Failure, heart attack, arrhythmias, pericardial effusion, peri-/myocarditis, hyper/hypotension, ischemia
2. Non-Hodgkin Lymphomas	1st line 1. R-CHOP: Rituximab, Cyclophosphamide, Vincristine, Prednisolone 2. R-da (dose adjusted) EPOCH: Rituximab, Etoposide, Vincristine, Doxorubicin, Cyclophosphamide, Prednisolone 3. CODOX-M/IVAC + R: Cyclophosphamide, Vincristine, Doxorubicin, High dose Methotrexate/ Ifosfamide, Etoposide, High Dose Cytarabine + Rituximab 4. R-Hyper—CVAD: Rituximab, Cyclophosphamide Vincristine, Doxorubicin, Dexamethasone/High Dose Methotrexate, High Dose Cytarabine 5. BR: Bendamustine, Rituximab	Arrhythmias, ischemia, heart failure, peri-/myocarditis, hyper/hypotension
3. Multiple Myeloma	1st line 1. VRd: Bortezomib, Lenalidomide, Dexamethazone 2. DRd: Daratumumab, Lenalidomide, Dexamethazone 3. CRd: Carfilzomib, Lenalidomide, Dexamethasone 4. VCd: Bortezomid, Cyclophosphamide, Dexamethazone 5. VAd: Bortezomib, Doxorubicin, Dexamethasone	Arrhythmias, atrial fibrillation, heart failure, myocarditis, hypertension
4. Acute Promyelocytic Leukemia	1st line 1. ATRA + Arsenic Trioxide (+/−Idarubicin, +/−Gemtuzumab Ozogamicin)	Pleural or pericardial effusion, Arterial and venous thrombosis, heart failure, QT prolongation
5. Acute Myeloid Leukemia	1. Idarubicin + Cytarabine (+/−Midostaurin, +/−Gemtuzumab Ozogamicin) 2. Azacitidine + Venetoclax 3. LDAC: Low dose Cytarabine + Venetoclax	Heart failure, arrhythmias, angina, pericarditis with effusion, QT prolongation, rarely edema, heart failure and myocardial infarction rarely induced by Venetoclax
6. Acute Lymphoblastic Leukemia	1. Hyper-CVAD +/− L-Asparaginase +/− TKI (Imatinibe, Dasatinib, Nilotinib, Bosutinib, Ponatinib) CVAD: Cyclophosphamide, vincristine, doxorubicin, dexamethasone	Heart failure and/or Myocarditis, pericardial effusion, hypertension, arrhythmia, QT interval prolongation, pulmonary arterial hypertension arrhythmias, hypertension, arterial thrombosis
7. Chronic Lymphocytic Leukemia	1. Ibrutinib 2. Venetoclax + Obinutuzumab 3. Bendamustine + Rituximab 4. FCR: Fludarabine, Cyclophosphamide, Rituximab	Atrial fibrillation, arrhythmias, hypotension, peri-/myocarditis